TABLE 3.
The associations between regular use of individual class of PPI/H2RA and risk of cholelithiasis.
| Cases | Person-years | Incidence rate a | HR (95%CI) b | RD (95%CI) b | |
|---|---|---|---|---|---|
| Regular use of PPIs | |||||
| Non-PPI user | 10,506 | 4,787,178 | 2.20 | 1.00 (Ref) | 1.00 (Ref) |
| Omeprazole user | 1,505 | 310,671 | 4.84 | 1.20 (1.13,1.28) | 3.18 (2.42, 3.76) |
| Lansoprazole user | 829 | 170,092 | 4.87 | 1.12 (1.03,1.21) | 2.30 (0.72, 3.28) |
| Esomeprazole user | 132 | 22,617 | 5.84 | 1.26 (1.06,1.51) | 4.30 (1.55, 5.41) |
| Other PPI user | 111 | 20,282 | 5.47 | 1.16 (0.96,1.41) | 3.09 (−1.27, 4.83) |
| Regular use of H2RAs | |||||
| Non-H2RA user | 12,420 | 5,165,809 | 2.40 | 1.00 (Ref) | 1.00 (Ref) |
| Ranitidine user | 422 | 98,042 | 4.30 | 1.14 (1.03,1.26) | 2.30 (0.65, 3.26) |
| Other H2RA user | 30 | 5,352 | 5.61 | 1.28 (0.90,1.84) | 4.29 (−3.81, 5.53) |
a
Per 1,000 person years.
b
Estimated effects were based on the fully adjusted model (see the footnote in Table 2).